Shots:
- Zealand Pharma has entered into a multi-program strategic collaboration & license agreement with OTR to discover & develop oral small molecules for metabolic diseases
- OTR & Zealand will jointly discover & develop multiple metabolic disease therapies, with OTR using its discovery platform to lead discovery & preclinical work while Zealand will handle global clinical development, regulatory filings, & commercialization
- As per the terms, OTR will receive $20M upfront (up to $30M with conditions), plus preclinical, development, regulatory & commercial milestones, representing the total deal value of ~$2.5B (majority tied to commercial milestones), along with tiered single-digit royalties on global net sales
Ref: Globe Newswire | Image: Zealand & OTR |Press Release
Related News: Pfizer Collaborates with YaoPharma in a ~$2.1B Licensing Deal for YP05002
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
